Published mark
Atea Pharmaceuticals, Inc.
NASDAQ: AVIR. Canonical company identity and public leadership record.
US
Record source reportedRecord not claimedNo Eval published
- Alpha ID
- alpha:company:b7501c6c-b71e-410c-9417-edc16acc3e24
- SEC CIK
- 0001593899
- Record version
- vpublic-1:ro-d751713988987e9331980363e24189ce, published Oct 22, 2026
- Newest evidence
- Mar 5, 2026
- Monitoring
- Not yet monitored Details
- Integrity
- Not yet signed Methodology
- CEO
- Jean-Pierre Sommadossi, Ph.D.Since Mar 5, 2026
- Chair
- Not published
- Independent
- 8 / 99 directors published
- Published claims
- 333 distinct sources
- Evidence records
- 90 pinned
- Source conflicts
- 0None open
Built from 3 distinct sources and 9 evidence records. Every Claim links to where it appears. Where nothing was published, the record states the coverage gap.
CorroboratedSource reportedAlpha inferenceNot disclosed
Public record. Alpha publishes governance facts about this organization from regulatory filings and company statements. Private enterprise overlay data is never projected here. The company can claim the record, correct, or dispute any Claim. How this works
CFO CHANGED
Andrea Corcoran executive of Atea Pharmaceuticals, Inc., effective 2026-03-05.
EffectiveEffective Mar 5, 2026E3
Monitoring
ContinuousWhat the published record states about identity, evidence, evaluation, monitoring, authority, and freshness. Watched-source schedules are not published for this record.
- IdentityunclaimedPublished
- Evidencesource_reportedPublished
- Evaluationnot_evaluatedPublished
- MonitoringNot yet published for this record.Not published
- AuthorityNot yet published for this record.Not published
- FreshnesscurrentPublished
Leadership
Evidence| Role | Person | Since | Status | Claim |
|---|---|---|---|---|
| Chief Financial Officer, Executive Vice President, Legal and Secretary | Andrea Corcoran | Mar 2026 | current | Source reportedE3 |
| Chief Development Officer | Janet Hammond, M.D., Ph.D. | Mar 2026 | current | Source reportedE4 |
| President and Chief Executive Officer and Chairman of the Board of Directors | Jean-Pierre Sommadossi, Ph.D. | Mar 2026 | current | Source reportedE5 |
| Chief Commercial Officer | John Vavricka | Mar 2026 | current | Source reportedE6 |
| Chief Medical Officer | Maria Arantxa Horga, M.D. | Mar 2026 | current | Source reportedE7 |
| Executive Vice President and Chief Accounting Officer | Wayne Foster | Mar 2026 | current | Source reportedE8 |
Board of directors
Evidence9 directors published. 8 of 9 with a published determination are independent.
| Director | Status | Since | Committees | Claim |
|---|---|---|---|---|
| Arthur Kirsch | Independent | 2025 | AuditAudit; Nominating and GovernanceNominating and Governance | Source reportedE2 |
| Barbara Duncan | Independent | 2020 | Audit, chairAudit · Chair; Nominating and GovernanceNominating and Governance | Source reportedE2 |
| Bruce W. Polsky, MD, MACP, FIDSA | Independent | 2014 | Compensation | Source reportedE2 |
| Bruno Lucidi | Independent | 2014 | AuditAudit; CompensationCompensation | Source reportedE2 |
| Franklin Berger | Independent | 2019 | AuditAudit; Compensation · ChairCompensation, chair | Source reportedE2 |
| Howard H. Berman, PhD | Independent | 2025 | None published | Source reportedE2 |
| Jean-Pierre Sommadossi, PhD | Not independent | 2014 | None published | Source reportedE2 |
| Jerome Adams, MD, MPH | Independent | 2021 | Nominating and Governance | Source reportedE2 |
| Polly A. Murphy, DVM, PhD | Independent | 2020 | Nominating and Governance, chairNominating and Governance · Chair | Source reportedE2 |
Committees and risk ownership
Evidence| Committee | Chair | Members | Risks assigned |
|---|---|---|---|
| Audit | Barbara Duncan | Barbara Duncan, Arthur Kirsch, Bruno Lucidi, Franklin Berger | Not described in the published record |
| Audit · Chair; Nominating and Governance | Not published | Barbara Duncan | Not described in the published record |
| Audit; Compensation | Not published | Bruno Lucidi | Not described in the published record |
| Audit; Compensation · Chair | Not published | Franklin Berger | Not described in the published record |
| Audit; Nominating and Governance | Not published | Arthur Kirsch | Not described in the published record |
| Compensation | Franklin Berger | Franklin Berger, Bruce W. Polsky, MD, MACP, FIDSA, Bruno Lucidi | Not described in the published record |
| Nominating and Governance | Polly A. Murphy, DVM, PhD | Polly A. Murphy, DVM, PhD, Arthur Kirsch, Barbara Duncan, Jerome Adams, MD, MPH | Not described in the published record |
| Nominating and Governance · Chair | Not published | Polly A. Murphy, DVM, PhD | Not described in the published record |
Committee RecordAudit: Chair Barbara Duncan; Members Barbara Duncan (Chair); Arthur Kirsch; Bruno Lucidi; Franklin Berger
Committee AppointmentBarbara Duncan: chair, Audit
Committee AppointmentArthur Kirsch: member, Audit
Committee AppointmentBruno Lucidi: member, Audit
Committee AppointmentFranklin Berger: member, Audit
Committee RecordCompensation: Chair Franklin Berger; Members Franklin Berger (Chair); Bruce W. Polsky, MD, MACP, FIDSA; Bruno Lucidi
Committee AppointmentFranklin Berger: chair, Compensation
Committee AppointmentBruce W. Polsky, MD, MACP, FIDSA: member, Compensation
Committee AppointmentBruno Lucidi: member, Compensation
Committee RecordNominating and Governance: Chair Polly A. Murphy, DVM, PhD; Members Polly A. Murphy, DVM, PhD (Chair); Arthur Kirsch; Barbara Duncan; Jerome Adams, MD, MPH
Committee AppointmentPolly A. Murphy, DVM, PhD: chair, Nominating and Governance
Committee AppointmentArthur Kirsch: member, Nominating and Governance
Committee AppointmentBarbara Duncan: member, Nominating and Governance
Committee AppointmentJerome Adams, MD, MPH: member, Nominating and Governance
Control and voting power
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Authority to act
Evidence and agent registryWho can act for the company, and on whose authority. This is what a counterparty's agent checks before it accepts an order, signs, or pays.
Principal executive officerJean-Pierre Sommadossi, Ph.D., President and Chief Executive Officer and Chairman of the Board of Directors, from Mar 5, 2026
Who can authorize an agentNot assessedNo Alpha inference about signing authority or board-reserved matters is published for this record.
Not assessed
AI agents registered by the companyNot registered in the public RegistryAgent Deployments, Agent Use Cases, Authority Grants, TrustChecks, Action Ledger entries and Governance Receipts live in the private enterprise overlay. They are never projected into the public Registry without explicit cross-plane authorization. Absence here is a plane boundary, not evidence that the enterprise operates no agents.
Agent registry
Delegations publishedNot disclosedBoard and officer delegation resolutions are not public filings and are not published in this record.
Search scope
Financials and market context
EvidenceSecurity ListingAVIR (NASDAQ)
Index membershipsNo current membership is published in Alpha's tracked index universe.This is not evidence that the company is absent from every market index.
None publishedAs of Oct 22, 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Governance and policies
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Risk, audit, and cyber
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
AI oversight and accountability
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Legal and regulatory
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Compensation
EvidenceNo published claims
Nothing is published for this section yet. A missing Claim is a coverage state, not a negative finding.
Other published claims
EvidencePublished Claims that belong to no section above. Each keeps its permalink, evidence, and assertion state.
Legal NameAtea Pharmaceuticals, Inc.
Entity StatusPublic listing published
Published FactUS
Not yet in this record
CoverageA gap is a coverage state, not a negative finding. These sections are expected for this entity class and are not yet published.
- Corporate structureNot reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- OwnershipNot reviewed. Ownership and voting power determine who can influence the board.
- FinancialsNot reviewed. Governance-relevant financial context frames capital and audit decisions.
- CompensationNot reviewed. Pay design shows how incentives are governed.
- GovernanceNot reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governanceNot reviewed. Meeting and vote records show shareholder dissent and support.
- AuditNot reviewed. Auditor, controls and restatements show assurance over reporting.
- LegalNot reviewed. Material legal and regulatory matters show enforcement exposure.
- RiskNot reviewed. Risk ownership links the board, committees, executives and controls.
- CyberNot reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governanceNot reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets externalNot reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.This Company Profile is an identity and evidence record, not an Alpha rating.
Linked people
Same claims as person records- Andrea CorcoranChief Financial Officer, Executive Vice President, Legal and Secretarycompany:b7501c6c-b71e-410c-9417-edc16acc3e24:leadership_role:14
- Janet Hammond, M.D., Ph.D.Chief Development Officercompany:b7501c6c-b71e-410c-9417-edc16acc3e24:leadership_role:15
- Jean-Pierre Sommadossi, Ph.D.President and Chief Executive Officer and Chairman of the Board of Directorscompany:b7501c6c-b71e-410c-9417-edc16acc3e24:leadership_role:16
- John VavrickaChief Commercial Officercompany:b7501c6c-b71e-410c-9417-edc16acc3e24:leadership_role:17
- Maria Arantxa Horga, M.D.Chief Medical Officercompany:b7501c6c-b71e-410c-9417-edc16acc3e24:leadership_role:18
- Wayne FosterExecutive Vice President and Chief Accounting Officercompany:b7501c6c-b71e-410c-9417-edc16acc3e24:leadership_role:19
- Arthur KirschDirectorcompany:b7501c6c-b71e-410c-9417-edc16acc3e24:leadership_role:5
- Barbara DuncanDirectorcompany:b7501c6c-b71e-410c-9417-edc16acc3e24:leadership_role:6
- Bruce W. Polsky, MD, MACP, FIDSADirectorcompany:b7501c6c-b71e-410c-9417-edc16acc3e24:leadership_role:7
- Bruno LucidiDirectorcompany:b7501c6c-b71e-410c-9417-edc16acc3e24:leadership_role:8
- Franklin BergerDirectorcompany:b7501c6c-b71e-410c-9417-edc16acc3e24:leadership_role:9
- Howard H. Berman, PhDDirectorcompany:b7501c6c-b71e-410c-9417-edc16acc3e24:leadership_role:10
- Jean-Pierre Sommadossi, PhDDirectorcompany:b7501c6c-b71e-410c-9417-edc16acc3e24:leadership_role:11
- Jerome Adams, MD, MPHDirectorcompany:b7501c6c-b71e-410c-9417-edc16acc3e24:leadership_role:12
- Polly A. Murphy, DVM, PhDDirectorcompany:b7501c6c-b71e-410c-9417-edc16acc3e24:leadership_role:13
Subject and corrections
Public-role doctrineThis record exists because the company is in the published Registry. The company can claim the record, correct, or dispute any Claim. Corrections are versioned and the original stays in history.
- Basis
- Published company record built from public sources
- Sources
- 9 evidence records cited. 0 with redistribution rights.
- Never published
- Private enterprise overlay data: deployments, authority grants, TrustChecks, receipts, telemetry
- Record claimed
- No
- Open disputes
- 0
- Identity ownership
- unclaimed
Claiming not yet available
If the company claims the record, its statements appear as their own assertion state and never overwrite the cited evidence.
Evidence
Authority and rights- E1Alpha canonical company public projection. canonical identity. Retrieved Oct 22, 2026. Cited by 4 Claims.
- E2sec proxy. Published Apr 29, 2025. Retrieved Apr 24, 2026. Cited by 9 Claims.
- E3sec filing. Published Mar 5, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
- E4sec filing. Published Mar 5, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
- E5sec filing. Published Mar 5, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
- E6sec filing. Published Mar 5, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
- E7sec filing. Published Mar 5, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
- E8sec filing. Published Mar 5, 2026. Retrieved May 14, 2026. Cited by 1 Claim.
- E9board_seats. board seats. Cited by 14 Claims.
What changed in version public-1:ro-d751713988987e9331980363e24189ce
vpublic-1:ro-d751713988987e9331980363e24189ce published Oct 22, 2026- Andrea Corcoran executive of Atea Pharmaceuticals, Inc., effective 2026-03-05.
- Janet Hammond, M.D., Ph.D. executive of Atea Pharmaceuticals, Inc., effective 2026-03-05.
- Jean-Pierre Sommadossi, Ph.D. executive of Atea Pharmaceuticals, Inc., effective 2026-03-05.
- John Vavricka executive of Atea Pharmaceuticals, Inc., effective 2026-03-05.
- Maria Arantxa Horga, M.D. executive of Atea Pharmaceuticals, Inc., effective 2026-03-05.
- Wayne Foster executive of Atea Pharmaceuticals, Inc., effective 2026-03-05.
- Arthur Kirsch seat on Atea Pharmaceuticals, Inc., effective 2025-01-01.
- Howard H. Berman, PhD seat on Atea Pharmaceuticals, Inc., effective 2025-01-01.
- Audit; Nominating and Governance committee of Atea Pharmaceuticals, Inc., effective 2025-01-01.
- Arthur Kirsch member of Audit; Nominating and Governance, effective 2025-01-01.
- Jerome Adams, MD, MPH seat on Atea Pharmaceuticals, Inc., effective 2021-01-01.
- Barbara Duncan seat on Atea Pharmaceuticals, Inc., effective 2020-01-01.
- Polly A. Murphy, DVM, PhD seat on Atea Pharmaceuticals, Inc., effective 2020-01-01.
- Audit · Chair; Nominating and Governance committee of Atea Pharmaceuticals, Inc., effective 2020-01-01.
- Barbara Duncan member of Audit · Chair; Nominating and Governance, effective 2020-01-01.
- Nominating and Governance · Chair committee of Atea Pharmaceuticals, Inc., effective 2020-01-01.
- Polly A. Murphy, DVM, PhD member of Nominating and Governance · Chair, effective 2020-01-01.
- Franklin Berger seat on Atea Pharmaceuticals, Inc., effective 2019-01-01.
- Audit; Compensation · Chair committee of Atea Pharmaceuticals, Inc., effective 2019-01-01.
- Franklin Berger member of Audit; Compensation · Chair, effective 2019-01-01.
- Bruce W. Polsky, MD, MACP, FIDSA seat on Atea Pharmaceuticals, Inc., effective 2014-01-01.
- Bruno Lucidi seat on Atea Pharmaceuticals, Inc., effective 2014-01-01.
- Jean-Pierre Sommadossi, PhD seat on Atea Pharmaceuticals, Inc., effective 2014-01-01.
- Audit; Compensation committee of Atea Pharmaceuticals, Inc., effective 2014-01-01.
- Bruno Lucidi member of Audit; Compensation, effective 2014-01-01.
- Bruce W. Polsky, MD, MACP, FIDSA member of Compensation, effective 2014-01-01.